ADPT Company Profile and Key Details

Q: Who are the executives of ADPT?

Dr. Mark Adams Ph.D.Chief Operating OfficerMr. Tycho W. PetersonChief Financial OfficerMr. Nitin SoodChief Commercial Officer of MRDMr. Christopher Carlson Ph.D.FounderMr. Yi ZhouChief Technical OfficerDr. Harlan S. Robins Ph.D.Co-Founder & Chief Scientific OfficerMs. Julie RubinsteinPres & Chief Operating OfficerMr. Kyle PiskelVice President & Principal Accounting OfficerYi ZhouChief Technical OfficerKarina CalzadillaVice President of Investor RelationsMs. Stacy L. TaylorSenior Vice President, Gen. Counsel & Corporation Sec.Mr. Chad M. Robins M.B.A, M.B.A.Co-Founder, Chief Executive Officer & ChairmanDr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine

NASDAQ : ADPT

Adaptive Biotechnologies

$13.30

-0.24-1.77%

Open: 12:45 PM

67.25

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Adaptive Biotechnologies Corporation (ADPT) stock declined over -1.77%, trading at $13.30 on NASDAQ, down from the previous close of $13.54. The stock opened at $13.42, fluctuating between $13.26 and $13.61 in the recent session.

Stock Snapshot

13.54

Prev. Close

2.13B

Market Cap

13.26

Day Low

-41.56

P/E Ratio

-0.32

EPS (TTM)

-1.15

Cash Flow per Share

13.42

Open

160.04M

Number of Shares

13.61

Day High

96.51%

Free Float in %

2.13

Book Value

412.03K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 11, 2026	13.91	14.10	13.43	13.54	1.51M
May 08, 2026	14.46	14.46	13.56	13.81	1.52M
May 07, 2026	14.58	15.06	14.22	14.69	1.95M
May 06, 2026	14.64	14.98	12.98	14.43	4.9M
May 05, 2026	14.74	14.83	13.64	13.78	3.12M
May 04, 2026	14.15	14.83	14.15	14.50	2.15M
Apr 30, 2026	13.54	14.16	13.54	14.10	1.19M
Apr 29, 2026	13.89	14.06	13.22	13.53	1.27M
Apr 28, 2026	14.21	14.30	13.71	14.04	1.19M
Apr 27, 2026	14.03	14.36	14.03	14.21	1.06M
Apr 23, 2026	14.18	14.45	13.50	13.82	1.01M
Apr 22, 2026	14.44	14.55	13.97	14.20	1M
Apr 21, 2026	14.59	15.15	14.16	14.21	1.46M
Apr 20, 2026	14.25	14.86	14.11	14.58	1.43M
Apr 17, 2026	14.55	14.91	14.39	14.47	1.57M
Apr 16, 2026	14.29	14.52	14.02	14.08	1.3M
Apr 14, 2026	14.17	14.80	14.08	14.53	1.36M
Apr 13, 2026	12.83	14.27	12.82	14.13	3.13M
Apr 10, 2026	13.43	13.60	12.36	12.79	3.25M
Apr 09, 2026	14.70	14.74	13.37	13.40	1.74M

Contact Details

Seattle, WA 98109

United States

https://www.adaptivebiotech.com 206 659 0067

About Company

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Stock Peers

ARGX

31.11+3.98%

argenx SE$813.28 REGN

-2.12-0.30%

Regeneron Pharmaceuticals, Inc.$712.77 UTHR

4.94+0.87%

United Therapeutics Corporation$569.88 MDGL

-13.01-2.55%

Madrigal Pharmaceuticals, Inc.$497.03 VRTX

5.35+1.24%

Vertex Pharmaceuticals Incorporated$435.17 PRAX

1.79+0.54%

Praxis Precision Medicines, Inc.$331.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

7.17+2.35%

Krystal Biotech, Inc.$312.88 ALNY

-10.21-3.46%

Alnylam Pharmaceuticals, Inc.$284.84 ASND

0.010.00%

Ascendis Pharma A/S$238.67

Company Overview

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) closed at $13.30 USD, losing -$0.24 (-1.77%) from the previous close of $13.54. The stock is currently mid-range between its 52-week high and low $8.50 and $20.76. With a market capitalization of about $2.13 billion, Adaptive Biotechnologies Corporation is classified as a mid-cap and shows higher-than-market volatility (beta ~2.16). Key stats such as the average daily volume over the past year has been around 1.93 million shares, volume is running light vs its 52-week average. Headquartered in Seattle, WA, Adaptive Biotechnologies Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chad Robins, the company employs approximately 619 people and listed since June 27, 2019. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 0.05%, SMA50 -2.41%, SMA200 17.17%). The stock’s 14-day RSI is 49.63 (neutral), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.71% below its high and over 163.15% above its low. Average 10-day trading volume of 2.52 million shares is slightly above the 3-month average of 1.99 million, indicating heightened recent market interest.

Valuation Metrics

Adaptive Biotechnologies Corporation trades at a P/E ratio of -42.17, slightly below the S&P 500 average, with a price-to-sales ratio of 7.3 and a price-to-book ratio of 9.68 trading at moderately above to book value. The P/FCF stands at -72.99, also below market averages.

Dividend & Fair Value

Adaptive Biotechnologies Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$14.64. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Adaptive Biotechnologies Corporation generated EPS of -$0.40 over the past year. Five-year average earnings growth is 18.85%. Wall Street analysts project EPS growth of 47.95% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.16. Next year's EPS is expected at $16.49. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 10 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $14.00. The high target offers 62.48% upside. The low target suggests 3.4% downside. The mean target is $18.83. This offers 39.07% upside. Adaptive Biotechnologies Corporation earnings surprise history is frequent misses against expectations. The quarter that ended May 05, 2026, missed forecasts by -18.75%. The prior quarter beat by -52.63%. Over the last six quarters, Apple has recorded several small beats. These include -14.81% in February 11, 2025.

Shareholding & Insider Activity

Adaptive Biotechnologies Corporation has 159.76 million shares outstanding. The public float is 119.31 million shares, elevated short interest at 6.76% of float. This equals 8.55 million shares. The short ratio is 4.16 days. Institutional investors hold 98.92% of the float. Insiders own 2.07%. ROBINS CHAD M holds 2.18 million shares, ROBINS HARLAN S has 1.51 million shares and PETERSON TYCHO has 531.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.79 million shares across 80 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Adaptive Biotechnologies generated $170.28M in revenue, or $1.18 per share. Gross margin was 42.57%, operating margin -118.40%, and net profit margin -132.29%. Returns are negative, with ROA at -34.07% and ROE at -73.04%.
On valuation metrics, Adaptive Biotechnologies trades at a P/E of -42.17, P/S of 7.30 and P/B of 9.68. The current ratio is 3.35 and quick ratio is 3.22. Operationally, the company’s inventory turnover is 6.52 and cash conversion cycle is 67.64 days. Debt-to-equity is 0.96, supported by a cash flow-to-debt ratio of -0.13.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Adaptive Biotechnologies posted revenue of $170.28M, down slightly from $185.31M in the prior quarter. Gross profit was $72.49M (margin 42.57%). Operating income was - $201.61M (margin -118.4%). Net income was- $225.25M (EPS - $1.56).
The company ended the quarter with $346.40M in cash and short-term investments, a total debt of $229.43M, and net debt of $164.37M. Total assets were $661.13M, with equity of $308.28M. Financials further reflected weakness, with operating cash flow of - $156.32M, free cash flow of - $167.02M, and capital expenditures of - $10.70M.

Price Forecast & Outlook

Our AI price prediction model suggests that Adaptive Biotechnologies Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.14%, with price expected at $14.10 by May 25, 2026, within a range of $13.51 to $14.72 3-Month Outlook: Projected rise of 9.16%, reaching $14.78 by August 07, 2026, with a range of $14.43 to $15.08. 1-Year Outlook: Projected gain of 141.8%, with price at $32.74 by May 11, 2027, within a range of $32.64 to $33.74.

Key Takeaways

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are up 10.04% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Adaptive Biotechnologies Corporation trading at a premium to the broader market with a P/E of -42.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.62, suggesting 44.9% upside. Our AI forecast model points to short-term strength (4.14% over two weeks), a medium-term rise (9.16% over three months), and a longer-term gain (141.8% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Adaptive Biotechnologies Corporation (ADPT) stock price?

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock price is $13.30 in the last trading session. During the trading session, ADPT stock reached the peak price of $13.61 while $13.26 was the lowest point it dropped to. The percentage change in ADPT stock occurred in the recent session was -1.77% while the dollar amount for the price change in ADPT stock was - $0.24.

ADPT's industry and sector of operation?

The NASDAQ listed ADPT is part of Biotechnology industry that operates in the broader Healthcare sector. Adaptive Biotechnologies Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADPT?

Dr. Mark Adams Ph.D.
Chief Operating Officer
Mr. Tycho W. Peterson
Chief Financial Officer
Mr. Nitin Sood
Chief Commercial Officer of MRD
Mr. Christopher Carlson Ph.D.
Founder
Mr. Yi Zhou
Chief Technical Officer
Dr. Harlan S. Robins Ph.D.
Co-Founder & Chief Scientific Officer
Ms. Julie Rubinstein
Pres & Chief Operating Officer
Mr. Kyle Piskel
Vice President & Principal Accounting Officer
Yi Zhou
Chief Technical Officer
Karina Calzadilla
Vice President of Investor Relations
Ms. Stacy L. Taylor
Senior Vice President, Gen. Counsel & Corporation Sec.
Mr. Chad M. Robins M.B.A, M.B.A.
Co-Founder, Chief Executive Officer & Chairman
Dr. Sharon Benzeno Ph.D.
Chief Commercial Officer of Immune Medicine

How ADPT did perform over past 52-week?

ADPT's closing price is 59.29% higher than its 52-week low of $8.50 where as its distance from 52-week high of $20.76 is -34.78%.

How many employees does ADPT have?

Number of ADPT employees currently stands at 619.

Link for ADPT official website?

Official Website of ADPT is: https://www.adaptivebiotech.com

How do I contact ADPT?

ADPT could be contacted at phone 206 659 0067 and can also be accessed through its website. ADPT operates from 1165 Eastlake Avenue East, Seattle, WA 98109, United States.

How many shares of ADPT are traded daily?

ADPT stock volume for the day was 412.03K shares. The average number of ADPT shares traded daily for last 3 months was 1.93M.

What is the market cap of ADPT currently?

The market value of ADPT currently stands at $2.13B with its latest stock price at $13.30 and 160.04M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	619
Beta	2.3
Sales or Revenue	$170.28M
5Y Sales Change%	1.234%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ADPT Company Profile and Key Details

Adaptive Biotechnologies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics